Radioligand Therapy Market to be dominated by Growing Prevalence of Cancer through 2027
Growing incidences of
prostate cancer and neuroendocrine tumors to drive the radioligand therapy
market in the forecast period, 2023-2027.
According to TechSci Research report, “Radioligand
Therapy Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2017-2027”, the global radioligand therapy market is
anticipated to grow at a significant rate in the forecast period, 2023-2027. The
increase in incidences of different types of cancer, and rising product
innovation and development due to technological advancements are the primary
factors driving the demand for the global radioligand therapy market. Growing awareness
of alpha radioimmunotherapy, rise in geriatric population, increasing
radioisotopes in healthcare, and heavy investments in healthcare sector are expected
to influence the market demand. Also, increasing strategic partnerships and
collaborations and rising per capita health care expenditure are also a key
factor for increasing the growth of the radioligand therapy market, globally.
However, the high cost associated with treatment
and complex reimbursement processes, increased competition from generics may
hamper the growth of the global radioligand therapy market may hamper the
growth of the global radioligand therapy market.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Radioligand Therapy Market"
The global radioligand
therapy market is segmented into indication, product, biomarker, end user and
company.
Based on indication, the
market is divided into prostate cancer, neuroendocrine tumor, and others. The prostate
cancer segment is expected to hold the largest market share. This is attributed
to the increasing number of patients suffering from prostate cancer, and growing
world population.
Based on product, the market
is divided into lutathera, zytiga, xtandi, and xofigo. The zytiga segment is
anticipated to grow during the forecast period. This is attributed to the
rising number of cases suffering from prostate cancer.
Based on biomarker, the
market is divided into prostate-specific membrane antigen, Ki 67 expression and
grading, cytochrome P450 17A1 inhibitor. The prostate-specific membrane antigen
segment is anticipated to grow during the forecast period. This is because it
is novel targeted therapy for metastatic prostate cancer.
Based on end user, the
market is divided into biotechnology & pharmaceutical companies, academic
& research institutions, and others. The academic & research
institutions segment is anticipated to grow during the forecast period. This is
attributed to the investments by governments for R&D activities, and
growing research and development activities to treat various kinds of cancers
is propelling the segment growth.
Major operating companies
operating in global radioligand therapy market are:
- Novartis International, AG
- Johnson & Johnson
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC.
- POINT Biopharma Global Inc
- Fusion Pharmaceuticals Inc.
- Clovis Oncology, Inc.
- Telix Pharmaceuticals Limited
- Lantheus Holdings, Inc.
- Progenics Pharmaceuticals
- Bayer AG
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the
market in 2021 and is expected to maintain its dominance in the coming years
due to the adoption of radioligand therapy products after FDA approval. The strongly
established research and healthcare infrastructure, rising emphasis on research
and development and clinical research activity for the treatment of cancer, several increasing developmental strategies, rising
awareness among population, and heavy investments by government in the region
is another key factor. Also, owing to numerous medical and
pharmaceutical companies in
the region are expected to propel the global Radioligand Therapy market growth
till 2027” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Radioligand Therapy Market
- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented
By Indication (Prostate Cancer, Neuroendocrine Tumor, Others), By Product
(Lutathera, Zytiga, Xtandi, Xofigo), By Biomarker (Prostate-Specific Membrane
Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By End
User (Biotechnology & Pharmaceutical Companies, Academic & Research
Institutions, Others), By Company, and By Region”, has evaluated the future growth
potential of global radioligand therapy market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global radioligand therapy market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com